202 related articles for article (PubMed ID: 32511656)
1. Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19.
Patterson BK; Seethamraju H; Dhody K; Corley MJ; Kazempour K; Lalezari JP; Pang AP; Sugai C; Francisco EB; Pise A; Rodrigues H; Ryou M; Wu HL; Webb GM; Park BS; Kelly S; Pourhassan N; Lelic A; Kdouh L; Herrera M; Hall E; Aklin E; Ndhlovu L; Sacha JB
medRxiv; 2020 May; ():. PubMed ID: 32511656
[TBL] [Abstract][Full Text] [Related]
2. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
[TBL] [Abstract][Full Text] [Related]
3. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.
Patterson BK; Seethamraju H; Dhody K; Corley MJ; Kazempour K; Lalezari J; Pang APS; Sugai C; Mahyari E; Francisco EB; Pise A; Rodrigues H; Wu HL; Webb GM; Park BS; Kelly S; Pourhassan N; Lelic A; Kdouh L; Herrera M; Hall E; Bimber BN; Plassmeyer M; Gupta R; Alpan O; O'Halloran JA; Mudd PA; Akalin E; Ndhlovu LC; Sacha JB
Int J Infect Dis; 2021 Feb; 103():25-32. PubMed ID: 33186704
[TBL] [Abstract][Full Text] [Related]
4. Is preexisting inflamed jaw marrow a "hidden" co-morbidity affecting outcomes of COVID-19 infections? - Clinical comparative study.
Lechner J; McMahon RE; Bouquot JE; Notter F; Schick F
Int J Immunopathol Pharmacol; 2024; 38():3946320241265265. PubMed ID: 38889772
[No Abstract] [Full Text] [Related]
5. Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning.
Patterson BK; Guevara-Coto J; Yogendra R; Francisco EB; Long E; Pise A; Rodrigues H; Parikh P; Mora J; Mora-RodrÃguez RA
Front Immunol; 2021; 12():700782. PubMed ID: 34262570
[TBL] [Abstract][Full Text] [Related]
6. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
9. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
Yao Z; Zheng Z; Wu K; Junhua Z
Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
[TBL] [Abstract][Full Text] [Related]
10. Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab.
Elneil S; Lalezari JP; Pourhassan NZ
J Transl Autoimmun; 2021; 4():100097. PubMed ID: 33778462
[TBL] [Abstract][Full Text] [Related]
11. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
13. Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.
Yin SW; Zhou Z; Wang JL; Deng YF; Jing H; Qiu Y
Virol J; 2021 Jun; 18(1):126. PubMed ID: 34118952
[TBL] [Abstract][Full Text] [Related]
14. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
16. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection.
Chen J; Lau YF; Lamirande EW; Paddock CD; Bartlett JH; Zaki SR; Subbarao K
J Virol; 2010 Feb; 84(3):1289-301. PubMed ID: 19906920
[TBL] [Abstract][Full Text] [Related]
17. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
18. CCR2 Signaling Restricts SARS-CoV-2 Infection.
Vanderheiden A; Thomas J; Soung AL; Davis-Gardner ME; Floyd K; Jin F; Cowan DA; Pellegrini K; Shi PY; Grakoui A; Klein RS; Bosinger SE; Kohlmeier JE; Menachery VD; Suthar MS
mBio; 2021 Dec; 12(6):e0274921. PubMed ID: 34749524
[TBL] [Abstract][Full Text] [Related]
19. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
20. Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.
Zuccon W; Comassi P; Adriani L; Bergamaschini G; Bertin E; Borromeo R; Corti S; De Petri F; Dolci F; Galmozzi A; Gigliotti A; Gualdoni L; Guerra C; Khosthiova A; Leati G; Lupi G; Moscato P; Perotti V; Piantelli M; Ruini A; Sportelli S; Susca M; Troiano C; Benelli G; Buscarini E; Canetta C; Merli G; Scartabellati A; Melilli B S C G; Sfogliarini R; Pellegatta G; Viganò G
Am J Emerg Med; 2021 Jul; 45():156-161. PubMed ID: 33046317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
